1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Asthma and Chronic Obstructive Pulmonary Disease: Asthma Ahead of COPD in Terms of Innovation with the Focus on Targeted Biologic Therapies for Severe Disease Phenotypes

Asthma and Chronic Obstructive Pulmonary Disease: Asthma Ahead of COPD in Terms of Innovation with the Focus on Targeted Biologic Therapies for Severe Disease Phenotypes

  • April 2019
  • 71 pages
  • ID: 5775887
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

Asthma and Chronic Obstructive Pulmonary Disease: Asthma Ahead of COPD in Terms of Innovation with the Focus on Targeted Biologic Therapies for Severe Disease Phenotypes

Summary
In terms of First-in-Class (FIC) product innovation, the Chronic Obstructive Pulmonary Disease (COPD) pipeline is lagging behind the asthma pipeline. Higher levels of First-in-Class (FIC) innovation in the asthma pipeline are focused on meeting the large unmet need for therapies which can treat severe asthma phenotypes.

Asthma and Chronic Obstructive Pulmonary Disease (COPD) are both highly prevalent, chronic, inflammatory diseases of the airways and lungs.The asthma market is highly saturated with relatively efficacious standard therapies and the Chronic Obstructive Pulmonary Disease (COPD)market is also highly saturated with therapies that help to prevent exacerbations of the disease.

However, there is considerable unmet need for innovative new therapies for severe asthmatics who do not respond to the current standards of care, and treatments which can reverse the progression of Chronic Obstructive Pulmonary Disease (COPD).

First-in-Class (FIC) product development in Chronic Obstructive Pulmonary Disease (COPD) constitutes only a small fraction of the pipeline.Of the pipeline products which had a disclosed molecular target, only 31% are FIC products.

In contrast, 41% of the asthma pipeline with a disclosed molecular target is a FIC product. Further to this, 66% of the First-in-Class (FIC) products in the Chronic Obstructive Pulmonary Disease (COPD) pipeline are found in the preclinical stage of development with no First-in-Class (FIC) products in Phase III development or later.

The industry average for First-in-Class (FIC) innovation within a disease area is approximately 40%, which means that not only is innovation in the Chronic Obstructive Pulmonary Disease (COPD) pipeline relatively low in comparison to the asthma pipeline, it is also much lower than the industry average. Combined with the lack of late-stage innovation, it is unlikely that any FIC products will be entering the Chronic Obstructive Pulmonary Disease (COPD) market in the near future.

There is a high unmet need for therapies that treat severe asthma and this is reflected in the asthma pipeline.Monoclonal antibodies (mAbs) are the second most common molecule type in the asthma pipeline, indicating high levels of interest in developing targeted biologic therapies for severe phenotypes of asthma.

The asthma market is saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs) and inhaled corticosteroids (ICSs). Therefore, the development of targeted biologic therapies for severe phenotypes of asthma is one way that companies can penetrate the asthma market.

The most prevalent molecular target class in the asthma pipeline is cytokines/chemokines and their receptors, which account for 18% of the pipeline.This group itself is diverse, although interleukins (ILs) and IL receptors are by far the most numerous targets among the cytokines, with IL-33, IL-4, IL-5 and IL-17 being targeted most frequently.

These ILs are heavily implicated in the inflammatory response, notably for their role in recruiting inflammatory cells such as eosinophils. The specificity of these therapies means they are highly effective in specific, more severe sub-types of asthma patients, such as those characterized by elevated levels of eosinophils.

The report "Asthma and Chronic Obstructive Pulmonary Disease: Asthma Ahead of COPD in Terms of Innovation with the Focus on Targeted Biologic Therapies for Severe Disease Phenotypes", assesses First-in-Class (FIC) innovation across the asthma and Chronic Obstructive Pulmonary Disease (COPD) pipelines.

Scope
- Both the asthma and COPD markets are highly saturated. Which drug classes are used to treat these disorders? How do the drug classes in the market compare with those in the pipelines?
- There are 266 and 161 pipeline programs in active development for asthma and COPD, respectively. What proportion of these products are first-in-class? How does first-in-class innovation vary by indication, development stage and molecular target class?
- Which molecular target classes are prominently represented in the first-in-class asthma and COPD pipelines? Which first-in-class targets have been identified as most promising for asthma and COPD, and is there any overlap?
- Which companies are the key players within the asthma and COPD markets? Who has been involved in the most licensing and co-development deals for asthma and COPD products? Which first-in-class products have prior deal involvement?

Reasons to buy
- Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems, epidemiology, and treatment options for both asthma and COPD.
- Visualize the composition of the asthma and COPD markets in terms of dominant molecule types and molecular targets. This allows an understanding of any gaps in the current market.
- Analyze and compare the asthma and COPD pipelines and stratify by stage of development, molecule type, and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products for each indication have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
- Recognize commercial opportunities by identifying first-in-class asthma and COPD pipeline products that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for asthma and COPD first-in-class products.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
25% Off

($6995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Prostaglandin D2 Receptor 2 - Pipeline Review, H2 2019

Prostaglandin D2 Receptor 2 - Pipeline Review, H2 2019

  • $ 3500
  • November 2019

Prostaglandin D2 Receptor 2 - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Prostaglandin D2 Receptor 2 - Pipeline Review, H2 2019’; Prostaglandin D2 Receptor 2 (Chemoattractant ...

House Dust Mite Allergy - Pipeline Review, H2 2019

House Dust Mite Allergy - Pipeline Review, H2 2019

  • $ 2000
  • September 2019

House Dust Mite Allergy - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide House Dust Mite Allergy - Pipeline Review, H2 2019, provides an overview of the ...

Grass Pollen Allergy - Pipeline Review, H2 2019

Grass Pollen Allergy - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Grass Pollen Allergy - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Grass Pollen Allergy - Pipeline Review, H2 2019, provides an overview of the Grass ...


ref:plp2019

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on